Compare Doses, Mechanisms & UK Availability Side-By-Side
Wegovy Dose Schedule Compared To Mounjaro: Key Differences
When comparing Wegovy dose to Mounjaro, the most significant difference lies in their escalation schedules and mechanisms of action. Wegovy follows a structured 16-week dose escalation from 0.25mg to the maintenance dose of 2.4mg, with each increase occurring every 4 weeks. Mounjaro uses a different schedule, starting at 2.5mg and increasing every 4 weeks up to a maximum of 15mg. Both treatments require gradual dose increases to minimise gastrointestinal side effects, but their target receptors differ fundamentally.
The mechanism distinction is crucial when weighing Wegovy dose compared to Mounjaro effectiveness. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural fullness hormone, reducing appetite and promoting satiety after smaller meals. Mounjaro contains tirzepatide, which targets both GIP and GLP-1 receptors simultaneously, potentially offering a dual approach to glucose regulation and weight management. Both medicines are prescription-only and must be used alongside a reduced-calorie diet and increased physical activity for optimal results.
UK Pricing Structure: Wegovy Compared To Mounjaro Costs
Understanding the financial commitment when comparing Wegovy dose to Mounjaro pricing helps inform your treatment choice. At EverydayMeds, Wegovy starts at £79.99 for the 0.25mg starter dose, progressing to £94.99 for 0.5mg, £99.99 for 1mg, £139.99 for 1.7mg, and £209.99 for the maintenance 2.4mg dose. Our Intro Duo bundle combines the first two doses (0.25mg and 0.5mg) for £169.99, providing eight weeks of initial treatment. New customers benefit from discount code FIRST40, while returning customers use DOSE25 at checkout.
Mounjaro pricing follows a different structure due to its distinct dosing schedule and mechanism. Both treatments represent significant monthly investments, making the choice between Wegovy dose compared to Mounjaro often dependent on individual response and prescriber recommendation. Our bundles offer convenience with Reliable Supply continuity—the Ultimate Stability Trio provides three months of 2.4mg Wegovy maintenance for £649.99. Both medications require ongoing prescription-only medicine status, ensuring regular clinical oversight throughout your weight management journey.
Clinical Evidence: Wegovy Dose Performance Compared To Mounjaro Studies
The STEP trial programme demonstrated Wegovy's efficacy across different populations, with patients achieving approximately 15% average weight loss at 68 weeks compared to 2.4% with placebo when used alongside diet and exercise. The STEP-2 trial specifically examined patients with type 2 diabetes, showing 9.6% weight reduction, while STEP-3 combined Wegovy with intensive behavioural therapy for 16% average weight loss.
When examining Wegovy dose compared to Mounjaro trial data, it's important to note that direct head-to-head comparisons aren't available due to different study designs and populations. Mounjaro's SURMOUNT trials used different endpoints and methodologies, making percentage comparisons inappropriate. Both treatments showed cardiovascular benefits—Wegovy's SELECT trial demonstrated a 20% reduction in major cardiovascular events, while Mounjaro studies focused on glucose control alongside weight management benefits.
How Wegovy Dosing Works: GLP-1 Mechanism Explained
Wegovy's semaglutide targets GLP-1 receptors in your brain's appetite control centres, mimicking the action of a natural hormone released after eating. This mechanism helps reduce food cravings and creates a feeling of fullness with smaller portions, supporting sustainable eating habit changes. The graduated dosing schedule allows your body to adjust gradually, starting with 0.25mg weekly injections and increasing every four weeks until reaching the therapeutic 2.4mg maintenance dose. Unlike Mounjaro's dual receptor approach, Wegovy focuses specifically on GLP-1 pathways, providing a well-established mechanism for appetite regulation. The once-weekly FlexTouch pen delivery system ensures consistent medication levels, supporting steady appetite control throughout your weight management programme.
UK Online Ordering Process: Assessment To Delivery
Purchasing Wegovy through EverydayMeds begins with our comprehensive 3-minute clinical assessment, covering your medical history, current medications, and weight management goals. Our UK-qualified prescribers review your assessment within standard 3 working days (or express 24-hour service), ensuring appropriate prescription-only medicine protocols are followed. Once approved, your genuine Novo Nordisk Wegovy ships via next-day delivery using temperature-controlled cold-chain logistics to maintain medication integrity. Our GPhC-registered pharmacy (#9012878) ensures full regulatory compliance throughout the process. The entire journey from assessment to doorstep typically takes 4-5 working days, with tracking provided for peace of mind during your weight management investment.
Storage Advantages: Wegovy Dose Compared To Mounjaro Practicality
Storage convenience represents a key practical difference when weighing Wegovy dose compared to Mounjaro for lifestyle integration. Wegovy pens can remain at room temperature (below 30°C) for up to 6 weeks once removed from refrigeration, compared to Mounjaro's 21-day room temperature limit. This extended stability makes Wegovy particularly suitable for frequent travellers or those with unpredictable schedules, reducing the stress of maintaining strict refrigeration requirements. Both medications require initial refrigerated storage between 2-8°C, but Wegovy's extended room temperature tolerance provides greater flexibility for real-world use. The FlexTouch pen design offers intuitive injection mechanics, while the predictable weekly dosing schedule (same day each week) simplifies routine establishment compared to other weight management approaches.
Wegovy Dose Escalation Compared To Mounjaro: Side Effect Management
The dose escalation strategy differs significantly when comparing Wegovy dose to Mounjaro protocols, directly impacting side effect tolerance and treatment continuation. Wegovy's 4-week intervals between dose increases allow thorough adaptation to gastrointestinal effects like nausea or reduced appetite, with each step representing a measured progression toward therapeutic levels. This gradual approach helps maintain treatment adherence, particularly important given weight regain potential if treatment discontinues prematurely. Mounjaro follows its own escalation pattern, designed specifically for tirzepatide's dual receptor mechanism and different pharmacokinetic profile.
Both medications can cause similar initial side effects, but the dose progression timing influences patient experience and long-term success. Clinical monitoring remains essential throughout either treatment, with prescriber guidance helping navigate any challenging adaptation periods. The structured approach to Wegovy dose compared to Mounjaro escalation reflects each medication's unique characteristics, ensuring optimal balance between therapeutic benefit and tolerability for sustainable weight management outcomes.
Complete Treatment Access: Both Options Available Through EverydayMeds
Rather than limiting choices, EverydayMeds provides access to both Wegovy and Mounjaro, allowing prescriber-guided treatment selection based on your individual clinical profile and preferences. Our clinical team evaluates factors including medical history, previous treatment responses, lifestyle considerations, and budget when recommending between these prescription-only medicines. Whether you proceed with Wegovy's established GLP-1 approach or Mounjaro's dual receptor mechanism, the same rigorous assessment and ongoing support structure applies. Code DOSE25 supports returning customers exploring alternative treatments, while our pharmacy maintains comprehensive stock levels to prevent treatment interruptions. Both Wegovy and Mounjaro are available from EverydayMeds—your prescriber can help determine which treatment aligns best with your weight management goals and clinical needs.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
